

a.) Amendments to the Claims

Claims 1-15 (Cancelled)

16. (Currently Amended) A pharmaceutical composition comprising a drug encapsulated in a liposome with an average particle size of 120 to 500 nm, and consisting of at least one lipid selected from the group consisting of hydrogenated soybean phosphatidylcholine, distearoyl phosphatidylcholine and polyethylene glycol-modified phospholipid having a phase transition temperature higher than *in vivo* temperature selected from the group consisting of phospholipid, glyceroglycolipid and sphingoglycolipid.

17. (Cancelled)

18. Cancelled)

19. (Currently Amended) The pharmaceutical composition liposome preparation according to claim 16, wherein the lipids are comprises at least one component selected from the group consisting of hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid.

20. (Currently Amended) The pharmaceutical composition liposome preparation according to claim 16, wherein the lipids are comprises at least one component selected from the group consisting of distearoyl phosphatidylcholine and polyethylene glycol-modified phospholipid.

21. (Cancelled)

22. (Currently Amended) The pharmaceutical composition liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is an indolocarbazole derivative.

23. (Currently Amended) The pharmaceutical composition liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is an antitumor agent.

24. (Currently Amended) The pharmaceutical composition liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is an antibiotic.

25. (Currently Amended) The pharmaceutical composition liposome preparation according to any one of claims 16, 19 and 20, wherein the drug encapsulated is a pharmaceutically active substance.

Claims 26-34 (Cancelled).

35. (Currently Amended) The pharmaceutical composition liposome preparation according to any one of claims 16, 19 or 20 wherein said liposome comprise comprises at least two bilayers of said lipid.

36. (Currently Amended) The pharmaceutical composition liposome preparation according to claim 22, wherein said liposome comprise comprises at least two bilayers of said lipid.

37. (Currently Amended) The pharmaceutical composition liposome preparation according to claim 23, wherein said liposome comprise comprises at least two bilayers of said lipid.

38. (Currently Amended) The pharmaceutical composition liposome preparation according to claim 24, wherein said liposome comprise comprises at least two bilayers of said lipid.

39. (Currently Amended) The pharmaceutical composition liposome preparation according to claim 25, wherein said liposome comprise comprises at least two bilayers of said lipid.

Claims 40-41 (Cancelled).

42. (New) A liposome preparation encapsulating a drug, comprising liposomes with an average particle size of 120 nm to 500 nm, wherein the liposomes are formed of lipid selected from the group consisting of hydrogenated soybean phosphatidylcholine, distearoyl phosphatidylcholine and polyethylene glycol-modified phospholipid.

43. (New) The liposome preparation according to claim 42, wherein the lipid is hydrogenated soybean phosphatidylcholine and polyethylene glycol-modified phospholipid.

44. (New) The liposome preparation according to claim 42, wherein the lipid is distearoyl phosphatidylcholine and polyethylene glycol-modified phospholipid.

45. (New) The liposome preparation according to any one of claims 42-44, wherein the drug is an indolocarbazole derivative.

46. (New) The liposome preparation according to any one of claims 42-44, wherein the drug is an antitumor agent.

47. (New) The liposome preparation according to any one of claims 42-44, wherein the drug is an antibiotic.

48. (New) The liposome preparation according to any one of claims 42-44, wherein the drug is a pharmaceutically active substance.